Acute tissue injury activates satellite cells and promotes sarcoma formation via the HGF/c-MET signaling pathway

Cancer Research

Volumn 75, Issue 3, 2015, Pages 605-614

  Van Mater, David ^a   Añó, Leonor ^a   Blum, Jordan M ^a   Webster, Micah T ^b   Huang, WeiQiao ^a   Williams, Nerissa ^a   Ma, Yan ^a   Cardona, Diana M ^a   Fan, Chen Ming ^b   Kirsch, David G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GEOPHYSICAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GUM TRAGACANTH; K RAS PROTEIN; PROTEIN P53; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TAMOXIFEN; TRANSCRIPTION FACTOR PAX7; CARDIOTOXIN; HGF PROTEIN, MOUSE; PAX7 PROTEIN, MOUSE; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; GASTROCNEMIUS MUSCLE; GENETIC RECOMBINATION; IMMUNOFLUORESCENCE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; SATELLITE CELL; SOFT TISSUE SARCOMA; SQUAMOUS CELL CARCINOMA; TIBIALIS ANTERIOR MUSCLE; TISSUE INJURY; ALLELE; ANIMAL; C57BL MOUSE; CYTOLOGY; FEMALE; METABOLISM; SARCOMA; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SOFT TISSUE TUMOR;

ALLELES; ANIMALS; CARDIOTOXINS; FEMALE; HEPATOCYTE GROWTH FACTOR; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; PAX7 TRANSCRIPTION FACTOR; PROTO-ONCOGENE PROTEINS C-MET; RAS PROTEINS; SARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84961288911     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2527     Document Type: Article

References (44)

1. Fletcher CDM, Unni KK, Mertens FWorld Health Organization International Academy of Pathology. Pathology and genetics of tumours of soft tissue and bone. Lyon Oxford: IARC Press; Oxford University Press (distributor); 2002.
2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD. [cited 2011 May 11]. Available from: http://seer.cancer.gov/csr/1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
3. Saab R, Spunt SL, Skapek SX. Myogenesis and rhabdomyosarcoma the Jekyll and Hyde of skeletal muscle. Curr Top Dev Biol 2011;94:197-234.
4. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov 2014;4:216-31.
5. Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 2013;24:710-24.
6. Blum JM, Ano L, Li Z, Van Mater D, Bennett BD, Sachdeva M, et al. Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells. Cell Rep 2013;5:933-40.
7. Rubin BP, Nishijo K, Chen HI, Yi X, Schuetze DP, Pal R, et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell 2011;19:177-91.
8. Dolberg DS, Hollingsworth R, Hertle M, Bissell MJ. Wounding and its role in RSV-mediated tumor formation. Science 1985;230:676-8.
9. Sieweke MH, Thompson NL, Sporn MB, Bissell MJ. Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta. Science 1990;248:1656-60.
10. Martins-Green M, Boudreau N, Bissell MJ. Inflammation is responsible for the development of wound-induced tumors in chickens infected with Rous sarcoma virus. Cancer Res 1994;54:4334-41.
11. Schuh AC, Keating SJ, Monteclaro FS, Vogt PK, Breitman ML. Obligatory wounding requirement for tumorigenesis in v-jun transgenicmice. Nature 1990;346:756-60.
12. Schuh AC, Keating SJ, Yeung MC, Breitman ML. Skeletal muscle arises as a late event during development of wound sarcomas in v-jun transgenic mice. Oncogene 1992;7:667-76.
13. Shalaby F, Schuh AC, Breitman ML. Two distinct target cells for v-jun mediated wound tumorigenesis. Oncogene 1994;9:2579-88.
14. Camboni M, Hammond S, Martin LT, Martin PT. Induction of a regenerative microenvironment in skeletal muscle is suf fi cient to induce embryonal rhabdomyosarcoma in p53-deficient mice. J Pathol 2012;226:40-9.
15. Webster MT, Fan CM. c-MET regulates myoblast motility and myocyte fusion during adult skeletal muscle regeneration. PLoS ONE 2013;8:e81757.
16. Lepper C, Conway SJ, Fan CM. Adult satellite cells and embryonic muscle progenitors have distinct genetic requirements. Nature 2009;460:627-31.
17. Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, Jessell TM, et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol 2001;1:4.
18. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and wide-spread neoplastic and developmental defects. Cancer Cell 2004;5:375-87.
19. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 2000;14:994-1004.
20. Huh CG, Factor VM, Sanchez A, Uchida K, Conner EA, Thorgeirsson SS. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A 2004;101:4477-82.
21. Kirsch DG, Dinulescu DM, Miller JB, Grimm J, Santiago PM, Young NP, et al. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 2007;13:992-7.
22. Moding EJ, Lee CL, Castle KD, Oh P, Mao L, Zha S, et al. Atm deletion with dual recombinase technology preferentially radiosensitizes tumor endothelium. J Clin Invest 2014;124:3325-38.
23. Mito JK, Min HD, Ma Y, Carter JE, Brigman BE, Dodd L, et al. Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma. J Pathol 2013;229:132-40.
24. Goetsch SC, Hawke TJ, Gallardo TD, Richardson JA, Garry DJ. Transcriptional profiling and regulation of the extracellular matrix during muscle regeneration. Physiol Genomics 2003;14:261-71.
25. White AC, Khuu JK, Dang CY, Hu J, Tran KV, Liu A, et al. Stem cell quiescence acts as a tumour suppressor in squamous tumours. Nat Cell Biol 2014;16:99-107.
26. Westphalen CB, Asfaha S, Hayakawa Y, Takemoto Y, Lukin DJ, Nuber AH, et al. Long-lived intestinal tuft cells serve as colon cancer-initiating cells. J Clin Invest 2014;124:1283-95.
27. Tatsumi R, Anderson JE, Nevoret CJ, Halevy O, Allen RE. HGF/SF is present in normal adult skeletal muscle and is capable of activating satellite cells. Dev Biol 1998;194:114-28.
28. Miller KJ, Thaloor D, Matteson S, Pavlath GK. Hepatocyte growth factor affects satellite cell activation and differentiation in regenerating skeletal muscle. Am J Physiol Cell Physiol 2000;278:C174-81.
29. Tidball JG. Inflammatory cell response to acute muscle injury. Med Sci Sports Exerc 1995;27:1022-32.
30. Heredia JE, Mukundan L, Chen FM, Mueller AA, Deo RC, Locksley RM, et al. Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. Cell 2013;153:376-88.
31. Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, et al. A special population of regulatory T cells potentiates muscle repair. Cell 2013;155:1282-95.
32. Murphy MM, Lawson JA, Mathew SJ, Hutcheson DA, Kardon G. Satellite cells, connective tissue fibroblasts and their interactions are crucial for muscle regeneration. Development 2011;138:3625-37.
33. Yang X, La Rosa FG, Genova EE, Huber K, Schaack J, Degregori J, et al. Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia. PLoS ONE 2013;8:e74809.
34. Ribeiro S, Napoli I, White IJ, Parrinello S, Flanagan AM, Suter U, et al. Injury signals cooperate with Nf1 loss to relieve the tumor-suppressive environment of adult peripheral nerve. Cell Rep 2013;5:126-36.
35. Maroun CR, Rowlands T. The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol Ther 2014;142:316-38.
36. Allen RE, Sheehan SM, Taylor RG, Kendall TL, Rice GM. Hepatocyte growth factor activates quiescent skeletal muscle satellite cells in vitro. J Cell Physiol 1995;165:307-12.
37. Rodgers JT, King KY, Brett JO, Cromie MJ, Charville GW, Maguire KK, et al. mTORC1 controls the adaptive transition of quiescent stem cells from G0 to G(Alert). Nature 2014;510:393-6.
38. O'Reilly C, McKay B, Phillips S, Tarnopolsky M, Parise G. Hepatocyte growth factor (HGF) and the satellite cell response following muscle lengthening contractions in humans. Muscle Nerve 2008;38:1434-42.
39. Sharp R, Recio JA, Jhappan C, Otsuka T, Liu S, Yu Y, et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med 2002;8:1276-80.
40. Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S, et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 2006;66:4742-9.
41. Rong S, Jeffers M, Resau JH, Tsarfaty I, Oskarsson M, Vande Woude GF. Met expression and sarcoma tumorigenicity. Cancer Res 1993;53:5355-60.
42. Scotlandi K, Baldini N, Oliviero M, Di Renzo MF, Martano M, Serra M, et al. Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol 1996;149:1209-19.
43. Oda Y, Sakamoto A, Saito T, Kinukawa N, Iwamoto Y, Tsuneyoshi M. Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma. HumPathol 2000;31:185-92.
44. Coley WB.II. The influence of injury upon the development of sarcoma. Ann Surg 1898;27:259-84.